Ahmet Sezer

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301

Byoung Chul Cho, Myung‐Ju Ahn, Jin Hyoung Kang et al. · Journal of Clinical Oncology · 2023 · 122 citations · Full text

Controlled release of piroxicam from chitosan beads

Ahmet Sezer · International Journal of Pharmaceutics · 1995 · 92 citations

Chitosan Beads, Engineering, Biotechnology +2

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

Mustafa Özgüroğlu, Ahmet Sezer, Mahmut Gümüş et al. · The Lancet Oncology · 2023 · 82 citations

First-line Cemiplimab Monotherapy, Empower-lung 1, Medicine +10

Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories

Amr F. Barakat, Sandeep Jain, Ahmad Masri et al. · JACC. Clinical electrophysiology · 2021 · 57 citations

Thrombosis, Venous Thrombosis, Direct Oral Anticoagulants +10

Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency

Nigar Taghizade, Royala Babayeva, Altan Kara et al. · Journal of Allergy and Clinical Immunology · 2023 · 36 citations · Full text

Primary Immunodeficiency, Translational Medicine, Autoimmune Disease +11